GHRS

$28.19-$2.05 (-6.78%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$2.1B

69M shares

52-week range

$11.83 – $31.44

83% from low

Exchange

NASDAQ

Change+$8.59

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-1.31	$-1.40–$-1.09	—	7
2027	$51M	—	$-1.86	$-2.39–$-1.40	—	7
2028	$3M	-93.6%	$-2.06	$-3.56–$-1.23	—	8
2029	$101M	+3022.4%	$-1.36	$-1.36–$-1.36	—	5

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 7 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-06	$-0.29	$-0.23	+19.6%
2026-05-14	$-0.27	$-0.31	-14.8%
2026-03-05	$-0.29	$-0.23	+20.7%
2025-11-06	$-0.23	$-0.23	+0.0%
2025-08-07	$-0.22	$-0.15	+31.8%
2025-05-08	$-0.61	$-0.19	+68.9%
2025-02-27	$-0.23	$-0.17	+26.1%
2024-11-14	$-0.25

DCF fair valuemodel estimate

Intrinsic value

$3.99

Price

$28.19

Implied downside

-86%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
GHRSGH Research PLC	$28.19	-6.78%	$1.9B	—
ABUSArbutus Biopharma Corp	$4.58	-0.22%	$905M	—
KURAKura Oncology, Inc.	$10.09	+1.51%	$896M	—
LENZLENZ Therapeutics, Inc.	$4.60	-8.73%	$144M	—
NBTXNanobiotix S.A.	$38.17	-3.22%

GH Research PLC Ordinary Shares

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

www.ghres.com

Employees: 73
IPO / List date: Jun 25, 2021

Held by traders on TradeandTell

No one on the platform currently holds GHRS.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2026-03-31	20,614	$289.8K

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded GHRS yet.

$GHRS chatter on StockTwits

Quantumup@Quantumup2d
BTIG⬆️ $STIM's PT to $6 and reiterated Buy. $CMPS $GHRS HELP JNJ ATAI - LLY DFTX Here's what BTIG said in its note in its note to investors: https://x.com/Quantumup1/status/2087240642426515579?s=20
View on StockTwits ↗
pedro@BiotechButterflies5d
$GHRS i remember when these were not even 1bn market cap.. just regretting I'd not doubled and trippled down....
View on StockTwits ↗
TheFly@theflynewsAug 6
Psychedelic: Compass Pathways, GH Research report quarterly earnings - $GHRS - https://thefly.com/GHRS
View on StockTwits ↗
JuliusW@JuliusWBullishAug 4
$ATAI $GHRS $HELP $DFTX holding HELP at this point, but all have done well...
View on StockTwits ↗
John Crawford@MajorBigBullBullishJul 27
$GHRS
View on StockTwits ↗
NOTRELOAD AI@notreload_aiJul 27
Wells Fargo projects branded psychedelics for depression reaching $11B by 2035. Details on Spravato and new ratings for $HELP, $GHRS, $CMPS, $DFTX. https://notreload.xyz/xy/wells-fargo-sees-psychedelics-market-hitting-11b-by-2035-help-ghrs-cmps-dftx/
View on StockTwits ↗
Squeezy@TheRealShortSqueezyBullishJul 21
🧬 $HELP : Could new yearly highs be coming? 📈 Helus Pharma continues to execute as it completed Phase 3 enrollment ahead of schedule for HLP003, keeping the company on track for a Q4 2026 topline data readout. Recent Progress: 🔸 Phase 3 enrollment completed ahead of schedule 🔸 FDA Breakthrough Therapy Designation already granted to HLP003 Technical Setup: 🔸 Higher highs and higher lows continue to develop 🔸 Price is approaching new yearly highs 🔸 Golden Cross (50/200 MA) could occur in the next few days 🔸 Key levels: $8.61 → $9.10 → $9.89 → $10.74 With momentum building both fundamentally and technically, HELP is entering an exciting period ahead of its next major catalyst. 📈 Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyHELP Sector Peers: $ATAI $CMPS $GHRS $NRXP
View on StockTwits ↗
Squeezy@TheRealShortSqueezyBullishJul 21
🚨 $HELP : NEWS JUST DROPPED! 📈 Helus Pharma announced it has completed enrollment ahead of schedule in its pivotal Phase 3 APPROACH trial evaluating HLP003 as an adjunctive treatment for major depressive disorder. The company remains on track for a Q4 2026 topline data readout. Today's Update ✅ Phase 3 enrollment is now complete, marking another major milestone before the upcoming data readout. ✅ The APPROACH study is one of three trials in Helus' Phase 3 PARADIGM program, supporting the potential path toward commercialization. ✅ Finishing ahead of schedule reflects strong execution as the trial moves into its final stage. ✅ Major depressive disorder affects more than 280 million people worldwide, highlighting the significant market opportunity for HLP003. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyHELP Sector Peers: $ATAI $CMPS $GHRS $NRXP
View on StockTwits ↗
Squeezy@TheRealShortSqueezyBullishJul 21
$HELP: Could Phase 3 Data Be the Next Major Catalyst? 📈 Helus Pharma is a clinical stage biotech developing next generation treatments for major depressive disorder and other mental health conditions. Its lead candidate, HLP003, remains on track for a Q4 2026 Phase 3 topline data readout. 🔬 Recent Highlights 🔹 Phase 3 enrollment has surpassed 86%, with topline data expected in Q4 2026. 🔹 FDA Breakthrough Therapy Designation supports an accelerated development pathway. 🔹 Completed a $50M financing, strengthening the balance sheet ahead of key milestones. 🔹 Big Pharma is validating the space. Eli Lilly's up to $3.8B psychedelic medicine acquisition and Johnson & Johnson's 66% YoY SPRAVATO sales growth to $438M reinforce the opportunity in next generation depression therapies. 🔹 Prior clinical data showed 100% response and 71% remission rates after two doses of HLP003. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyHELP Sector Peers: $ATAI $CMPS $GHRS $NRXP
View on StockTwits ↗
George Jetson@GeorgeJetson17Jul 21
@PreGigs What a long, strange trip it’s been - congrats on the gains! My long-term shares are almost the same ($1.48/share) and like you, feeling a little lost. Like someone else mentioned, I think it’s worth holding onto ATAI until the sale finalizes so you have the ability to make an extra $2.50/share via the CVRs. I swore I was going to be done with single stock investing after ATAI, IMHO, selling us out like they did, but I calculated my post-taxes profits pre-CVRs and rolled them into $CMPS. I’m not nearly as bullish, but I wanted to have some skin in game in the space, think $DFTX is currently valued too high for a new investment and that $HELP is too much a gamble, so went with CMPS. You could also split some $ between 2 or 3 of them, or even $GHRS . Otherwise, I’d just put the funds into a mixture of ITOT and IXUS, which is what I’m doing with the money outside of what I put into CMPS. Let us know what you decide!
View on StockTwits ↗
Matthew 'Whiz' Buckley@WhizBuckleyJul 17
$ATAI word salad for "I needed the money" https://christianangermayer.substack.com/p/my-love-letter-to-psychedelics-and $DFTX $CMPS $HELP $GHRS
View on StockTwits ↗
STACKD0E@STACKD0EBullishJul 17
$GHRS WE DID IT!! 🙃 ✨️
View on StockTwits ↗
TNN Stock Analysis@TNNStockAnalysisNewsJul 17
Top Stock Gainers Today (Wednesday, July 16, 2026) $ABT – +10.70% $ATAI – +32.93% $UNH – +4.27% $MMM – +3.70% $GHRS – +19% https://truthsandnews.com/markets/top-stock-gainers-today-july-16-2026-abbott-ataibeckley
View on StockTwits ↗
STACKD0E@STACKD0EBullishJul 17
$JBHT $MATX $HUBG $GHRS $FOXF ✨
View on StockTwits ↗
T@Roaring_CapybaraJul 17
$GHRS Small, early stages, but HUGE potential psychedelic - for treatment of multiple applications such as pain, depression, and anxiety = MIRA. They have Ketamir-2 in their pipeline which provides similar relief as ketamine, but unlike ketamine and its other derivatives ......... it is NOT classified as a controlled substance. This will make prescribing and treatment with Ketamir-2 far more easier for doctors and far less restrictive for patients...
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.